{'fraction_non_alphanumeric': 0.033815330220751554, 'fraction_numerical': 0.01885680612846199, 'mean_word_length': 5.241018387553041, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 5, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Osteogenesis Imperfecta/Ehlers–Danlos Overlap Syndrome and Neuroblastoma—Case Report and Review of Literature

Osteogenesis imperfecta/Ehlers–Danlos (OI/EDS) overlap syndrome is a recently described disorder of connective tissue, characterized by mutation of COL1A1 (17q21.33) or COL1A2 (7q21.3) genes, that are involved in α-1 and α-2 chains of type 1 collagen synthesis. The clinical spectrum of this new clinical entity is broad: patients could present a mixed phenotype that includes features of both osteogenesis imperfecta (bone fragility, long bone fractures, blue sclerae, short stature) and Ehlers–Danlos syndrome (joint hyperextensibility, soft and hyperextensible skin, abnormal wound healing, easy bruising, vascular fragility). We reported the case of a young Caucasian girl with severe short stature and a previous history of neuroblastoma, who displayed the compound phenotype of OI/EDS. Next generation sequencing was applied to the proband and her parent genome. Our patient presented a de novo heterozygous COL1A1 variant (c.3235G>A, p.Gly1079Ser), whose presence might be indicative of diagnosis of OI/EDS overlap syndrome. We also hypothesize that the association with the previous history of neuroblastoma could be influenced by the presence of COL1A1 mutation, whose role has been already described in the behavior and progression of some cancers.


Introduction
Osteogenesis imperfecta (OI) is an inherited and rare disorder of connective tissue with a broad clinical spectrum, usually characterized by skeletal deformities, osteopenia, blue sclerae, dentinogenesis imperfecta, and extremely fragile bones [1].
Between 85% and 90% of individuals with OI have autosomal dominant mutations of COL1A1 and/or COL1A2 genes, that are involved in α-1 and α-2 chains of type 1 collagen synthesis [2,3] the most abundant extracellular matrix (ECM) component in various tissues and organs.
The OI Mutation Consortium has identified a large number of COL1A1/COL1A2 mutations are secondary to the substitution of glycine residues in the type 1 collagen chain [4].
We described the case of a Caucasian young girl, followed in our Pediatric Endocrinology Outpatient Clinic for severe short stature, who presented a de novo heterozygous mutation c.3235G>A [p.(Gly1079Ser)] of COL1A1 gene associated with a history of neuroblastoma and a clinical phenotype compatible with a OI/EDS syndrome.

Study Design
For this study we have a case report on the clinical features and next generation sequencing of a patient with clinical features compatible with OI/EDS overlap syndrome and a previous history of neuroblastoma. The patient's parents were also assessed in order to confirm the results.

Case Description
The proband was a 10-year-old Caucasian girl, who came to our attention due to a severe short stature.
Family history was unremarkable. She was born at 38 weeks of gestational age within the lower limits of auxological birth parameters (birth length: −1.57 SDS and birth weight: −1.48 SDS). During the first months of life, she presented feeding problems and needed enteral nutrition via naso-gastric tube for 3 months.
A series of investigations were performed in order to exclude cystic fibrosis, urinary tract infection, metabolic diseases, congenital heart malformations, celiac disease: sweat test, urinalysis, serum and urinary amino acids dosage, echocardiogram, screening for celiac disease, and sialotransferrin isoelectric focusing (IEF) were normal.
Conventional karyotyping and chromosomal microarray analysis did not show chromosomal anomalies. Mutational analysis of SHOX gene was performed by MLPA analysis followed by gene sequencing to exclude a frequent cause of short stature.
Imprinting disorders, particularly Silver-Russell syndrome and Prader-Willi syndrome were tested and excluded.
At the age of 11 months, she was diagnosed with stage 4 MYCN nonamplified neuroblastoma with left adrenal and bone marrow invasion, successfully treated with left adrenalectomy followed by 6 chemotherapy courses of the carboplatin-etoposide association. The tumoral response was complete and no further relapses were detected in the following years.
Therefore, at the age of 9 years, due to a severe and worsening height deficit hormonal causes of short stature (growth hormone deficit, hypothyroidism, hypercortisolism) were investigated and then excluded; a brain MRI did not show median line alterations and only the presence of arachnoidal cyst in the right temporo-polar region was detected.
Clinical examination at 10 years of age revealed a condition of severe short stature with 2 years delayed bone age: height was 119.5 cm (−3.06 SDS), weight 23.4 kg (−0.76 SDS) and bone age 8.25 years. The child's height was about 4 SDS lower than target height (TG 1.19 SDS), her height velocity during the last year was significantly reduced (−2.12 SDS) and no signs of incipient pubertal development were detectable (B1/Ph1 according to Tanner's stage).
She had pale and mild hyperelastic skin, bilateral ectropion, and blue sclerae ( Figure 1). Joint hypermobility of large and of finger joints (Beighton score 7/9), scoliotic curvature of the spine, tooth decay, and mild changes in tooth enamel were other prominent phenotypic features. There was no abnormality in scarring and no muscular weakness.
Laboratory tests for complete blood count, hepatic and renal function, electrolytes, thyroid hormones dosage, and also the evaluation of vitamin D and parathormone levels were confirmed normal, similarly to growth hormone (GH) stimulated levels.
Audiometric examination and ocular evaluation were normal. Bone density study with dual-energy X-ray absorption (DEXA) showed a markedly reduced bone mineralization (femoral BMD Z score −4.3 SDS and lumbar Z-score −3.3 SDS) [17].
of the spine, tooth decay, and mild changes in tooth enamel were other prominent phenotypic features. There was no abnormality in scarring and no muscular weakness. Laboratory tests for complete blood count, hepatic and renal function, electrolytes, thyroid hormones dosage, and also the evaluation of vitamin D and parathormone levels were confirmed normal, similarly to growth hormone (GH) stimulated levels.
Audiometric examination and ocular evaluation were normal. Bone density study with dual-energy X-ray absorption (DEXA) showed a markedly reduced bone mineralization (femoral BMD Z score −4.3 SDS and lumbar Z-score −3.3 SDS) [17].
Despite a negative history of fractures, the presence of joint hypermobility, short stature, blue sclerae, and tooth enamel alterations led us to hypothesize an inherited genetic condition, such as COL1-related overlap disorder. For this reason, and after genetic counseling, a test was performed using next-generation sequencing (NGS) technology.

Samples
Patient's genomic DNA, clinical data, and photographs were collected and analyzed for both diagnosis and research purposes. Written informed consent was provided and signed by both parents.

Next Generation Sequencing
Enrichment and parallel sequencing were performed on genomic DNA extracted from circulating leukocytes of the affected subjects and unaffected parents. Library preparation was carried out by using a Twist Custom Panel (clinical exome-Twist Bioscience), according to the manufacturer's protocol, and sequenced on a NovaSeq6000 (Illumina) platform. A short stature gene panel was assessed which included the following genes: Sequencing data were aligned to the hg19 human reference genome. Based on the guidelines of the American College of Medical Genetics and Genomics, a minimum depth coverage of 30X was considered suitable for analysis.
Mutations identified as pathogenic were confirmed by Sanger sequencing, following a standard protocol (BigDye Terminator v3.1 Cycle Sequencing Kit, Applied Biosystems by Life Technologies, Waltham, MA, USA). Despite a negative history of fractures, the presence of joint hypermobility, short stature, blue sclerae, and tooth enamel alterations led us to hypothesize an inherited genetic condition, such as COL1-related overlap disorder. For this reason, and after genetic counseling, a test was performed using next-generation sequencing (NGS) technology.

Samples
Patient's genomic DNA, clinical data, and photographs were collected and analyzed for both diagnosis and research purposes. Written informed consent was provided and signed by both parents.

Next Generation Sequencing
Enrichment and parallel sequencing were performed on genomic DNA extracted from circulating leukocytes of the affected subjects and unaffected parents. Library preparation was carried out by using a Twist Custom Panel (clinical exome-Twist Bioscience), according to the manufacturer's protocol, and sequenced on a NovaSeq6000 (Illumina) platform. A short stature gene panel was assessed which included the following genes: Sequencing data were aligned to the hg19 human reference genome. Based on the guidelines of the American College of Medical Genetics and Genomics, a minimum depth coverage of 30X was considered suitable for analysis.
Mutations identified as pathogenic were confirmed by Sanger sequencing, following a standard protocol (BigDye Terminator v3.1 Cycle Sequencing Kit, Applied Biosystems by Life Technologies, Waltham, MA, USA).
This variant was not present in DNA samples of the parents. It was not reported in the frequency database of the general population and was described in the literature in association with OI [18,19] and could be classified as a pathogenic variant (class 5), according to the American College of Medical Genetics and Genomics (ACMG) guidelines [20].

Discussion and Review of Literature
We described a case of a young girl with a de novo missense heterozygous mutation c.3235G>A p.Gly1079Ser of COL1A1 gene, already described in the literature in association with type I and IV OI [18,19], and a clinical phenotype compatible with a OI/EDS syndrome. To the best of our knowledge, this is the first case of OI/EDS overlap syndrome associated with this heterozygous COL1A1 variant.
According to Cabral et al. [21] and Malfait et al. [16], OI/EDS syndrome could be defined as a generalized connective tissue disorder characterized by features of both osteogenesis imperfecta (bone fragility, long bone fractures, blue sclerae, short stature) and Ehlers-Danlos syndrome (joint hyperextensibility, soft and hyperextensible skin, abnormal wound healing, easy bruising, vascular fragility).
Literature data about this complex and rare syndrome are very few. Most recent reports, made by Morlino et al. [13], described clinical and molecular features of 21 individuals, firstly ascertained by a clinical suspicion of EDS, in whom a wide spectrum of COL1A1 and COL1A2 heterozygous variants (that usually cause OI) were detected.
OI/EDS syndrome is clinically heterogeneous and no conventional criteria are still available to define this condition. The identification of these patients is consequently usually difficult: they are often classified within the variability of a broader definition of OI or diagnosed with a form of EDS featuring some of the minor clinical manifestations of OI [13].
The name of the syndrome has also been questioned and some authors proposed the broad nomenclature of "COL1-related overlap disorder" (C1ROD) to indicate an intermediate/mixed phenotype at the between of EDS and OI. This entity is characterized by the presence of causative variants in COL1A1 and COL1A2 genes in individuals with EDS typical phenotype (associated or not with signs of mild-moderate OI) that does not strictly coincide with a certain type of mutation of type I collagen gene [13].
The identification of causative variants in COL1A1 or COL1A2 genes is necessary for confirming the diagnosis of C1ROD.
Morlino et al. [13] identified a number of major and minor diagnostic criteria for C1ROD whose presence should be addressed to perform specific molecular testing.
Major criteria are represented by the presence of blue sclerae, flatfeet with valgus deformity, generalized joint hypermobility according to age, and significantly soft and doughy and/or hyperextensible skin.
Dolichostenomelia (arm span/height ratio > 1.05 in adult only); hearing loss; short stature (<2 DS); two or more atrophic (non-papyraceous) scars; two or more fractures in prepubertal age; two or more joint dislocations; and two or more injuries and/or ruptures of ligaments, tendons, and/or muscle were reported by Morlino et al. as minor criteria.
Molecular testing in index patients with suspected C1ROD should be performed in presence of three or four major criteria or two major criteria plus two or more minor criteria or one major criterion and five or more minor criteria [12].
We hypothesize that our case could be considered as an unusual variant of OI/EDS syndrome because of the coexistence of typical elements of EDS arthrochalase (such as joint hypermobility and mildly hyperelastic skin) in addition to the aforementioned OI phenotype.
In our case, we identified the presence of three major criteria (blue sclerae, generalized joint hypermobility according to age, and hyperextensible skin) and one minor criterion (short stature), so we decided to include molecular testing for C1ROD with NGS technology in our diagnostic workup.
NGS technology is considered a powerful approach to detect COL1A1 and COL1A2 mutations associated with connective tissue disorders, such as OI or EDS. Prior to its application, biochemical collagen analysis of fibrillar collagen proteins was used to identify the defect responsible for the phenotypical features observed in patients with suspected OI or EDS. Testing sensitivity is high for both types of investigations, but it is not clear if the sensitivity is additive [7].
To date, a combined approach with biochemical collagen analysis and NGS technologies could be considered in patients in whom the diagnosis in unclear, including those with OI/EDS overlap syndrome [11].
The majority of OI/EDS overlap syndrome patients displayed a heterozygous variant in the N-terminal part of the type I collagen helical region in either the α-1 or α-2 chain Genes 2022, 13, 581 6 of 13 which affects-to some extent-proper processing of the N-propeptide [16,22], and results in the formation of small and weak collagen fibrils with irregular contours [20]. Glycine substitutions are frequently found in patients with a mixed OI/EDS phenotype [16] and condition clinical presentation.
This glycine residue appears to be evolutionally highly conserved if this change induces a small physicochemical difference between glycine and serine. Glycine residues within the Gly-Xaa-Yaa repeats of the triple helix domain are required for the structure and stability of fibrillar collagens [23][24][25]. Experimental studies show that this missense change (p.Gly1079Ser) results in minor helix destabilization [26] at the C-terminal region. For these reasons, this variant is classified as pathogenic.
Furthermore, as previously described [18], changes affecting glycine residues could be responsible of an OI phenotype characterized by low bone mineral density, short stature, dentinogenesis imperfecta, and scoliosis, as with our patient. On the other hand, EDS features seem to be more evident in individuals with abnormal/delayed type I procollagen N-propeptide processing, due to variants affecting the N-terminal of α-1 and α-2 procollagen [16].
In our case, the initial suspicion was about a mild form of OI. Additionally, the type of mutation found-classified as pathogenic variant (class V)-has been already reported to segregate with type I OI in several families [26][27][28][29]. First description was made in 1992 and interested Italian patients from the same family [26]. It has also been detected in many individuals and families with OI types I, III, and IV [19,[30][31][32][33][34].
To date, 23 individuals with this p.Gly1079Ser mutation of COL1A1 gene have been described in literature [4,6,19,28,30,32] and all identified as OI subtypes: 8 patients were diagnosed with type IV OI, 14 were classified as suffering from type I OI, and 1 case remained undetermined. There are both sporadic and familial cases and a broad phenotypic variability has been observed, also among the same family members. This different genotype-phenotype correlation is not clear and could be related to the influence of other genes and environmental factors on clinical presentation [35].
Short stature was a prominent feature of our patient, however her stimulated GH and basal IGF1 levels were normal and other endocrinological causes of short stature were ruled out because of the normality of hormone dosages.
Severe short stature may be common, but it is a not well-studied feature in OI patients which usually presents growth failure and compromised final height [36].
Growth impairment in OI patients usually starts since toddler age and is mainly due to the absence of osteoanabolic stimuli, secondary to defects in collagen structure that alter chondrocyte maturation and influence the so called "functional muscle-bone-unit" activity [37][38][39].
The severity of growth failure is strictly dependent on the OI severity, so it is more severe in patient with type 3 OI, who reach a final height of less than 100 cm [40].
This complex etiology could also explain the lack of effectiveness of attempts with GH treatment [41], whose secretion rate is usually normal [41] and whose action on growth velocity could depend probably on the underlying disease [42].
Short stature is rarely observed among EDS patients, excepting for the rare "Ehlers-Danlos syndrome, spondylodysplastic form type 3", secondary to recessive loss-of-function variants in SLC39A13, a zinc transporter gene [43,44]; however, it has been described as a common clinical feature among patients with "OI/EDS overlap syndrome" (Table 1). In our patient's history, feeding problems had been a remarkable feature. In a cohort of patients with OI/EDS overlap syndrome [13] a condition of neonatal hypotonia was reported, but no mention of feeding problems was present. This element is increasingly found among patients with several genetic diseases, and often its presence could be a signal of a specific disease (e.g., Prader-Willi syndrome) [45].
We could not say whether in our girl this condition was related to neonatal hypotonia or whether it was a direct consequence of her genetic defect.
Additionally, the incipient neuroblastoma could justify its presence. The association with a past history of neuroblastoma is another important element in our Case Report. Malignancies are rarely described among OI patients [46] and an alleged biochemical resistance to cancer of these individuals was suggested [47].
Osteosarcoma is the most frequent malignancies among OI patients [48,49] and might be probably secondary to the strong irradiation they are exposed to because of the great number of diagnostic radiographs of fractured bones, as reported in previous studies. Moreover, sporadic cases of tumors derived from breast, ovarian, colon, and gastric epithelium were described [45,[50][51][52][53][54][55]. Furthermore, malignant tumors are also infrequent in patients with EDS and no cases of neoplasms have been, until now, reported in patients with OI/EDS syndrome.
NB is an embryonic developmental malignancy derived from sympathetic neural crest cells that usually affects children less than 18 months of age. It presents different phenotypes, that range from spontaneously regressive forms to metastatic and fatal disease, especially children older than 18 months at the time of diagnosis [56,57].
Stage 4 NB affects patients less than 18 months of age and it is characterized by the presence of metastasis to bone with or without manifestations in other metastatic sites [58]. Children with stage 4 nonamplified MYCN disease show a better outcome even with reduced treatment [59].
Genetic predisposition to NB development has been associated with common and rare genetic germline mutations [57]. At a somatic level, NB tumors show relatively few recurrent alterations, with point mutations in ALK (8-10%) and in ATRX (1-2%) being the most frequent [57]. A possible explanation for the association between COL1A1 mutation and NB could be given by recent genomic analysis suggesting COL1A1 playing a role in NB development. Indeed, our whole exome and deep sequencing study found somatic pathogenic mutations occurring in collagen type family genes-including COL1A1-in a subset of high-risk NBs [60]. While a cis-regulatory network analysis of NB reported COL1A1 as a relevant gene regulated by a super enhancer involved in the modulation of NB cell identity [61].
Moreover, COL1A1 is indicated as a predisposition gene in pediatric cancers [62]. Finally, COL1A1 seems to also play a role in initiation and progression of other cancers, such as colon cancer [63], gastric cancer [64], esophageal cancer [65], and ovarian cancer [66].
We are not able to explain how the presence of COL1A1 mutation could influence NB onset or progression in our patient. The link between both the diseases currently remains only a hypothesis based on the observation of a single case and further studies are needed to confirm our assumption.

Conclusions
The presence of COL1A1 c.3235G>A variant might be suggestive of a diagnosis of OI/EDS overlap syndrome. We also could hypothesize that the observed association with the previous history of neuroblastoma is not incidental, but it could be influenced by the presence of COL1A1 mutation, whose role in some cancers behavior and progression has been already described.  Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki. Ethical review and approval were waived for this study because this is an observational single patient case report.
Informed Consent Statement: Informed consent was obtained from our patient's parents to publish this paper.
Data Availability Statement: Not applicable.